Denali & Biogen halt BIIB122 in idiopathic Parkinson's after Phase 2b miss; BEACON continues

Denali Therapeutics Inc.

Phase 2b LUMA study of BIIB122 (DNL151) in 648 early-stage Parkinson's patients failed primary and secondary endpoints.
BIIB122 did not slow disease progression vs placebo on MDS-UPDRS Part II+III combined score.
Biogen and Denali discontinue further development of BIIB122 in idiopathic Parkinson's disease.
Denali continues independent Phase 2a BEACON study in LRRK2 pathogenic variant carriers; data expected H1 2027.
Biomarker data showed >90% peripheral LRRK2 kinase inhibition and ~30% CSF pRab10 reduction.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.